TriSalus Life Sciences (TLSI) Projected to Post Earnings on Monday

TriSalus Life Sciences (NASDAQ:TLSI) is anticipated to announce its earnings results before the market opens on Monday, April 7th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. TriSalus Life Sciences has set its FY 2025 guidance at EPS.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.35) EPS for the quarter, meeting analysts’ consensus estimates of ($0.35). The company had revenue of $8.26 million for the quarter, compared to analyst estimates of $8.12 million. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Stock Performance

TriSalus Life Sciences stock opened at $5.22 on Friday. The stock has a market cap of $159.17 million, a PE ratio of -2.10 and a beta of 0.48. The stock has a 50-day moving average price of $5.44 and a 200 day moving average price of $4.75. TriSalus Life Sciences has a 52 week low of $3.50 and a 52 week high of $10.42.

Insiders Place Their Bets

In other TriSalus Life Sciences news, CFO James Emmett Young purchased 24,000 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The stock was purchased at an average cost of $5.40 per share, with a total value of $129,600.00. Following the transaction, the chief financial officer now owns 24,000 shares in the company, valued at approximately $129,600. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Mary T. Szela purchased 5,030 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was bought at an average price of $5.03 per share, with a total value of $25,300.90. Following the completion of the acquisition, the chief executive officer now owns 439,249 shares in the company, valued at $2,209,422.47. This represents a 1.16 % increase in their position. The disclosure for this purchase can be found here. Insiders bought 54,856 shares of company stock worth $294,608 over the last three months. 32.80% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on TLSI shares. Canaccord Genuity Group restated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, March 28th. Cantor Fitzgerald started coverage on TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price objective for the company. Lake Street Capital initiated coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They issued a “buy” rating and a $10.00 target price for the company. Finally, Roth Mkm reissued a “buy” rating and issued a $11.00 price target on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, TriSalus Life Sciences presently has a consensus rating of “Buy” and an average target price of $11.56.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.